BioAtla, Inc. (BCAB)
About BioAtla, Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $300.0K
- Net income
- -$59.6M
- Total assets
- $13.8M
- Market cap
- $5.5M
- Operating margin
- -2965.2%
- Net margin
- -2980.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.0M
- Operating expenses
- $61.3M
- Operating income
- -$59.3M
- Income tax
- $0
- Net income
- -$59.6M
- EPS (basic)
- $-1.01
- EPS (diluted)
- $-1.01
Balance sheet
- Total assets
- $13.8M
- Current assets
- $8.0M
- Total liabilities
- $50.0M
- Current liabilities
- $21.9M
- Shareholders’ equity
- $36.2M
Cash flow
- Operating cash flow
- -$48.2M
- Investing cash flow
- $41.9M
- Financing cash flow
- $6.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.5M
- EPS (diluted)
- $-1.01
- Shares outstanding
- 1.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 16, 2020
BioAtla, Inc. (BCAB) Stock Price
- Reported a net loss of $59.6M in FY2021.
- Revenue grew 567% from FY2021 to FY2025.
- Trading 94% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BioAtla, Inc..
Write a review
News about BioAtla, Inc.
News & sentiment via Polygon.io
BioAtla, Inc.: frequently asked questions
Is BioAtla, Inc. an American company?
BioAtla, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is BioAtla, Inc. headquartered?
BioAtla, Inc. is headquartered in San Diego, California, United States.
Is BioAtla, Inc. publicly traded?
Yes — BioAtla, Inc. is a publicly traded company. Its stock trades under the ticker symbol BCAB on the NASDAQ.
What does BioAtla, Inc. do?
BioAtla, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
